Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gilberto Zavala

Internal Medicine Chicago, IL Medical Doctor

NPI 1699700872 CMS profile 212977

1725 W Harrison St, Sutie 318, Chicago, IL 60612

Open in the dashboard

General payments

$6,401

313 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gilberto Zavala of Chicago, IL is reported in the CMS Open Payments database as having received $6,401 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $253 11
2023 General $921 41
2022 General $1,085 51
2021 General $1,652 84
2020 General $914 47
2019 General $1,577 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gilberto Zavala
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gilberto Zavala were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gilberto Zavala Internal Medicine median Middle half National median
2019 $1,577 $159 $48–$570 $163
2020 $914 $119 $33–$402 $114
2021 $1,652 $135 $37–$521 $132
2022 $1,085 $141 $42–$496 $149
2023 $921 $149 $45–$519 $160
2024 $253 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Pfizer Inc. $1,143 48 payments
  2. Novo Nordisk Inc $958 44 payments
  3. AbbVie, Inc. $946 49 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $420 18 payments
  5. Amgen Inc. $363 20 payments
  6. Novartis Pharmaceuticals Corporation $315 16 payments
  7. Kowa Pharmaceuticals America, Inc. $289 16 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $234 14 payments
  9. Sanofi Pasteur Inc. $179 8 payments
  10. Astellas Pharma US Inc $178 5 payments
  11. Other $1,375 75 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $6,302 312 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2024
  1. ELIQUIS $627 23 payments
  2. Ozempic $527 24 payments
  3. RYBELSUS $446 20 payments
  4. LINZESS $384 20 payments
  5. CREON $358 20 payments
  6. Prolia $318 18 payments
  7. EVENITY $307 17 payments
  8. ENTRESTO $290 15 payments
  9. Livalo $282 15 payments
  10. Bystolic $222 13 payments
  11. Other $5,845 294 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

539

Median for Internal Medicine: 777

Drug cost

$15,043

Median for Internal Medicine: $73,373

Branded share of claims

16%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Glyxambi Empagliflozin/Linagliptin Brand 12 $7,379
Synthroid Levothyroxine Sodium Brand 13 $1,183
Temazepam Generic 11 $686
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $654
Nebivolol Hcl Generic 12 $603
Amlodipine Besylate-Benazepril Amlodipine Besylate/Benazepril Brand 14 $586
Atorvastatin Calcium Generic 46 $456
Levothyroxine Sodium Generic 31 $431
Losartan Potassium Generic 21 $328
Lisinopril Generic 18 $295

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$36,420

Of which drugs: $155

Medicare patients

121

Average age 75

Services billed

581

65 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 21%
Ischemic heart disease 21%
Osteoporosis 16%
Cancer 15%
Heart failure 11%
Atrial fibrillation 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $107
$107 — —
ELIQUIS
  • PFIZER INC. $26
$26 — —
NURTEC ODT
  • PFIZER INC. $26
$26 — —
PAXLOVID
  • PFIZER INC. $26
$26 — —
RYBELSUS
  • Novo Nordisk Inc $12
$12 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record